Compare Citius Pharmaceuticals Inc (CTXR) vs iShares MSCI Canada (TSX) (EWC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares MSCI Canada (TSX) — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while iShares MSCI Canada (TSX) trades at $61.51. The key difference: iShares MSCI Canada (TSX) is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | EWC | |
|---|---|---|
Market Cap | $18.73M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $61.51 |
52-Week Low | $0.48 | $47.00 |
Enterprise Value | $14.95M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
EWC, the iShares MSCI Canada ETF, trades at $61.30, up 0.99% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The fund faces headwinds from renewed U.S.-Canada trade tensions, including 50% tariffs announced in July 2026, though bullish analyst views highlight resilience due to energy and potash exclusions. Key financial ratios are unavailable in the provided data.
Outlook is mixed: technical strength supports near-term gains, but trade policy risks and overbought conditions warrant caution. Investment appeal hinges on Canada's resource-heavy economy navigating tariffs, with diversification benefits for U.S. investors. Risks include escalated trade war impacts on Canadian exports and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →
